Neurotherapeutics最新文献

{"title":"Preclinical Evaluation of Drug-Induced Sensory Neuropathy: A Veterinary Toxicologic Pathologist’s Perspective","authors":"Deepa B. Rao BVSc, MS, PhD, DABT, DACVP, FIATP","doi":"10.1016/j.neurot.2026.e00988","DOIUrl":"10.1016/j.neurot.2026.e00988","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00988"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"NUZ-001 Restores Neurotrophic Support and Enhances Autophagy in Cellular and Zebrafish Models of Huntington’s Disease","authors":"Jeffrey Brown PhD","doi":"10.1016/j.neurot.2026.e00992","DOIUrl":"10.1016/j.neurot.2026.e00992","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00992"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951310","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Clinical Update: NRTX-1001 GABAergic Interneuron Cell Therapy for Drug-Resistant Focal Epilepsy","authors":"John Hixson MD, Jerry Shih, Sharona Ben-Haim, Robert Beach, Harish Babu, David Spencer, Kim Burchiel, Rebecca O'Dwyer, Sepehr Sani, Derek Southwell, Matthew Luedke, Gautam Banik, Marina Bershteyn, Alessandro Bulfone, Brianna Feld, Luis Fuentealba, Stephanie Hughes, Ji-Hye Jung, Tia Kowal, Sonja Kriks, Cory Nicholas","doi":"10.1016/j.neurot.2026.e00985","DOIUrl":"10.1016/j.neurot.2026.e00985","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00985"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951318","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Post Hoc Analysis of RESCUE Trial Shows Shortened Hospital Stay and Higher Rate of Discharge to Home in Participants Treated with RNS60","authors":"Supurna Ghosh, Jordan S. Dubow, Jocelyn Sutherland, Andreas Kalmes, Jarrad Mock, Sameer A. Ansari, Christopher G. Favilla, David Chiu, Wayne M. Clark, David S. Liebeskind, Ryan A. McTaggart","doi":"10.1016/j.neurot.2026.e01016","DOIUrl":"10.1016/j.neurot.2026.e01016","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e01016"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Human immunocompetent 3D neural spheroid assay platform for high throughput screening and therapeutic development","authors":"Jiajing Zhang PhD, Yi Wei Lim PhD, Angelica Medina PhD, Yu-Chi Chen, Martin Carrasco Carvajal, Marc Ferrer PhD, Emily Lee PhD","doi":"10.1016/j.neurot.2026.e01007","DOIUrl":"10.1016/j.neurot.2026.e01007","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e01007"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951515","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Long-term efficacy of subthalamic nucleus deep brain stimulation in focal motor seizures and implications for candidate selection","authors":"Baoxin Xu,&nbsp;Xueyuan Wang,&nbsp;Xiaohua Zhang,&nbsp;Liang Qiao,&nbsp;Wei Shu,&nbsp;Duanyu Ni,&nbsp;Xiaoming Yan,&nbsp;Liankun Ren,&nbsp;Guoguang Zhao,&nbsp;Tao Yu","doi":"10.1016/j.neurot.2026.e00950","DOIUrl":"10.1016/j.neurot.2026.e00950","url":null,"abstract":"<div><div>Focal motor seizures (FMS) are often unresectable because of motor risk. We aimed to evaluate the long-term effectiveness and safety of subthalamic nucleus deep brain stimulation (STN-DBS) in patients with FMS and to identify suitable candidate patients. We analyzed long-term outcomes in 22 patients with FMS treated with STN-DBS, classifying patients as responders (≥50% seizure reduction) or non-responders and relating outcomes to seizure-focus topography using focus-frequency maps and region-of-interest–based volumetrics. In a SEEG cohort of 13 patients with electrodes in the sensorimotor cortex and the STN, including 1 from the DBS cohort, we quantified changes in interictal spike (IIS) rates and broadband (0.5–90 Hz) power spectral density (PSD) across distinct sensorimotor subregions during 100-Hz STN stimulation. At final follow-up (mean 45 months), median seizure reduction was 55%, with 14/22 responders and six patients achieved &gt;90% reduction, including one seizure-free. STN-DBS was well tolerated, with no surgical complications and one explant for infection. Responders’ seizure foci clustered in a medial sensorimotor strip comprising the paracentral lobule (PCL), supplementary motor area (SMA) and trunk representations of the precentral and postcentral gyri, and greater involvement of the PCL and trunk areas correlated with better outcome. SEEG analyses showed a global reduction in broadband power but regionally selective suppression of epileptiform activity, confined to the PCL and SMA. Together, STN-DBS appears to be a safe, effective option for FMS, and patients whose seizure foci involve the medial sensorimotor strip may be potential candidates.</div></div>","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00950"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148318183","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Sotagliflozin improves cognitive deficits and attenuates neuroinflammation of Alzheimer's disease","authors":"Yuye Ning,&nbsp;Meilin Chen,&nbsp;Hao Yang,&nbsp;Jianping Jia","doi":"10.1016/j.neurot.2026.e00946","DOIUrl":"10.1016/j.neurot.2026.e00946","url":null,"abstract":"<div><div>Effective treatments for Alzheimer's disease (AD) are limited. Due to shared pathological mechanisms between AD and diabetes, antidiabetic drugs like sodium-glucose cotransporter-2 inhibitors (SGLT2is) are potential therapeutic options. Although SGLT2is have shown cognitive benefits in diabetes models, their effects in AD models are not fully established. This study aimed to evaluate the therapeutic effects of sotagliflozin (Sota), an SGLT2i, in both in vivo and in vitro AD models. The network pharmacology analysis was used to predict the potential targets and pathways of Sota. And we selected 6-month-old APP/PS1 transgenic mice to investigate the effects of Sota. Cognitive function was assessed using the Morris water maze test. Immunohistochemistry and immunofluorescence were employed to quantify amyloid-beta (A<em>β</em>) plaque deposition in the hippocampal or cortex and analyze neuronal loss. Additionally, amyloid <em>β</em> oligomers induction and microglial cells were used to evaluate the effects of Sota on the release of pro-inflammatory mediators and to investigate the underlying mechanisms. In vivo, Sota treatment improved cognitive impairments, reduced pro-inflammatory cytokines, inhibited microglial activation, and promoted neuronal survival. In vitro, Sota mitigated A<em>ß</em> oligomer-induced toxicity in microglial cells by decreasing reactive oxygen species and pro-inflammatory cytokine release. Mechanistically, Sota treatment was associated with suppression of extracellular signal-regulated kinase (ERK) signaling. Our findings suggest that Sota improved cognitive impairment and attenuates neuroinflammation in AD. Sota may be a promising candidate for the treatment of AD.</div></div>","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00946"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148376392","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Personalizing neuromodulation for chronic pain: A connectivity-guided trial","authors":"Enrico De Martino,&nbsp;Margit Midtgaard Bach,&nbsp;Bruno Nascimento Couto,&nbsp;Anne Jakobsen,&nbsp;Pedro Nascimento Martins,&nbsp;Stian Ingemann-Molden,&nbsp;Adenauer G. Casali,&nbsp;Thomas Graven-Nielsen,&nbsp;Daniel Ciampi de Andrade","doi":"10.1016/j.neurot.2026.e00960","DOIUrl":"10.1016/j.neurot.2026.e00960","url":null,"abstract":"<div><div>In this randomized, double-blind, controlled trial, we evaluated 8 weeks of repetitive transcranial magnetic stimulation (rTMS) for chronic pain, comparing classic primary motor cortex (M1) stimulation with a novel target-selection strategy based on pre-therapy cortical connectivity. Guided by homeostatic plasticity, we hypothesized that stimulating the cortical site with the lowest pre-therapy global connectivity would produce more pain relief than stimulating the site with the highest connectivity or stimulating M1 independent of connectivity. Before treatment, TMS-evoked EEG potentials were recorded from four cortical targets: M1, dorsolateral prefrontal cortex, anterior cingulate cortex, and posterosuperior insular cortex. For each target, connectivity was quantified using a distance-weighted, phase-based measure (debiased weighted phase lag index, wPLI) that reflects the magnitude and spatial extent of TMS-induced oscillatory phase locking across cortical regions. Ninety patients with chronic pain were randomized to Low-Connectivity, High-Connectivity, or Classic-M1 groups and received 12 rTMS sessions over 8 weeks. The primary outcome was the proportion of patients achieving at least 30% reduction in pain intensity. Secondary outcomes included pain intensity, pain interference, sleep, fatigue, mood, quality of life, and patient global impression of change. No significant between-group differences were observed for primary or secondary outcomes (all p &gt; 0.05). In prespecified mechanistic exploratory analyses, lower pre-therapy local M1 connectivity was associated with greater pain reduction in the Classic-M1 group (r = 0.50, p = 0.005), but not in the Low- or High-Connectivity groups. These findings suggest that global connectivity-based target selection did not enhance analgesic efficacy and that the local M1 associations are hypothesis-generating and require prospective validation.</div></div>","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00960"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148456558","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Trajectory guide for minimally-invasive MRI-guided neurosurgery: Accelerating intraparenchymal therapeutic delivery through a simplified workflow with fewer scanning steps","authors":"Thomas Lilieholm PhD,&nbsp;Terrence R. Oakes PhD,&nbsp;Andrew L. Alexander PhD,&nbsp;Azam Ahmed MD,&nbsp;Walter F. Block PhD","doi":"10.1016/j.neurot.2026.e01014","DOIUrl":"10.1016/j.neurot.2026.e01014","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e01014"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951316","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

{"title":"Advancing Disease Monitoring in Huntington’s Disease Using a Multi-Modal Digital Health Technology","authors":"Ashkan Vaziri PhD,&nbsp;Ram Kinker Mishra,&nbsp;Jamie L. Adam MD","doi":"10.1016/j.neurot.2026.e00995","DOIUrl":"10.1016/j.neurot.2026.e00995","url":null,"abstract":"","PeriodicalId":19159,"journal":{"name":"Neurotherapeutics","volume":"23 4","pages":"Article e00995"},"PeriodicalIF":7.4,"publicationDate":"2026-07-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"148951437","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}